Skip to main navigation
Skip to search
Skip to main content
University of Nottingham Ningbo China Home
Home
Profiles
Research units
Research output
Projects
Prizes
Activities
Press/Media
Impacts
Student theses
Search by expertise, name or affiliation
View Scopus Profile
Jun Xia
Co-Director of GRADE Centre (Ningbo)
School of Economics
Email
Jun.Xia
nottingham.edu
cn
h-index
3915
Scopus Citations
31
h-index
Calculated based on number of publications stored in Pure and citations from Scopus
2005
2024
Research activity per year
Overview
Fingerprint
Network
Projects
(15)
Research output
(96)
Activities
(1)
Fingerprint
Dive into the research topics where Jun Xia is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Acne
12%
Acupuncture
20%
Adverse Effects
13%
Adverse Events
29%
Antipsychotics
26%
Assessment Development
9%
Attention Deficit Hyperactivity Disorder
12%
Atypical Antipsychotics
14%
Basal Insulin
12%
Cancer Pain
12%
China
15%
Clinical Practice Guidelines
11%
Cochrane
30%
Cochrane Review
15%
Cochrane Systematic Review
12%
Cognitive Behavioral Therapy
8%
Confidence Interval
100%
COVID-19
13%
Embase
18%
Evaluation Assessment
9%
Evidence-based Clinical Practice Guideline
12%
Extracted Data
9%
Grading of Recommendations
9%
Hydromorphone
12%
Inter-rater Reliability
10%
MEDLINE
19%
Mental States
9%
Meta-analysis
43%
Network Meta-analysis
14%
Number-needed-to-treat
11%
People with Schizophrenia
22%
Pharmacological Intervention
13%
Placebo
31%
Psychoeducation
12%
Quality of Life
13%
Randomized Clinical Trial
9%
Randomized Controlled Trial
58%
Relative Risk
13%
Review Authors
11%
Risk of Bias
26%
Risk Ratio
55%
Risperidone
11%
Schizophrenia
94%
Search Methods
10%
Selection Criteria
13%
Severe Mental Illness
16%
Systematic Meta-analysis
37%
Tinnitus
12%
Tolerability
8%
Type 2 Diabetes Mellitus (T2DM)
12%
Pharmacology, Toxicology and Pharmaceutical Science
2 Hydroxyacid
5%
Acne
8%
Adverse Event
41%
Antipsychotic
20%
Attention Deficit Disorder
8%
Atypical Antipsychotics
14%
Azelaic Acid
8%
Cancer Pain
12%
Chemoradiation Therapy
12%
Chemotherapy
8%
Cholinesterase Inhibitor
8%
Clinical Trial
5%
Clozapine
5%
Controlled Clinical Trial
5%
Delirium
8%
Disease
10%
Ginkgo Biloba
8%
Group Trial
6%
Hydromorphone
12%
Infection
6%
Nasopharynx Carcinoma
8%
Negative Syndrome
5%
Nicotinamide
8%
Non Insulin Dependent Diabetes Mellitus
8%
Number Needed to Treat
10%
Overall Survival
5%
Placebo
30%
Quetiapine
6%
Randomized Clinical Trial
10%
Randomized Controlled Trial
81%
Rheumatoid Arthritis
8%
Risperidone
11%
Salicylic Acid
8%
Sulfur
8%
Symptom
10%
Tinnitus
12%
Tolerability
8%
Tripterygium wilfordii
8%
Typical Antipsychotic
19%
Medicine and Dentistry
2 Hydroxyacid
5%
Acneiform Eruption
12%
Adolescent
8%
Adverse Event
15%
Attention Deficit Disorder
8%
Auriculotherapy
20%
Azelaic Acid
8%
Chinese Herbal Medicine
8%
Clinician
9%
Cognitive Behavioral Therapy
8%
COVID-19
8%
Dance Therapy
8%
Drug Therapy
9%
Group Trial
6%
Hearing Impairment
8%
Infection
7%
Maturity Onset Diabetes of the Young
8%
Meta-Analysis
24%
Network Meta-Analysis
12%
Neuropathic Pain
8%
Nicotinamide
8%
Placebo
10%
Pneumonia
8%
Quality of Life
9%
Randomized Controlled Trial
53%
Rheumatoid Arthritis
8%
Salicylic Acid
8%
Sequela
8%
Sulfur
8%
Symptom
5%
Systematic Review
51%
Topical Treatment
5%
Tripterygium wilfordii
8%
Typical Antipsychotic
13%
